Skip Navigation
ChemIDplus A TOXNET DATABASE LiteBrowseAdvanced

Substance Name: Triazolam [USAN:USP:INN:BAN:JAN]
RN: 28911-01-5
UNII: 1HM943223R
InChIKey: JOFWLTCLBGQGBO-UHFFFAOYSA-N

Note

  • A short-acting benzodiazepine used in the treatment of insomnia. Some countries temporarily withdrew triazolam from the market because of concerns about adverse reactions, mostly psychological, associated with higher dose ranges. Its use at lower doses with appropriate care and labeling has been reaffirmed by the FDA and most other countries.

Molecular Formula

  • C17-H12-Cl2-N4

Molecular Weight

  • 343.216
 

Classification Codes

Classification Codes

  • Adjuvants, Anesthesia
  • Anti-Anxiety Agents
  • Central Nervous System Agents
  • Central Nervous System Depressants
  • Drug / Therapeutic Agent
  • GABA Agents
  • GABA Modulators
  • Human Data
  • Neurotransmitter Agents
  • Psychotropic Drugs
  • Reproductive Effect
  • Sedative-Hypnotic
  • Tranquilizing Agents

Superlist Classification Code

  • DEA Schedule IV

Names and Synonyms

Name of Substance

  • Triazolam
  • Triazolam [USAN:USP:INN:BAN:JAN]

MeSH Heading

  • Triazolam

Synonyms

  • 4H-(1,2,4)Triazolo(4,3-a)(1,4)benzodiazepine, 8-chloro-6-(2-chlorophenyl)-1-methyl-
  • 8-Chloro-6-(2-chlorophenyl)-1-methyl-4H-(1,2,4)triazolo(4,3-a)(1,4)benzodiazepine
  • 8-Chloro-6-(o-chlorophenyl)-1-methyl-4H-s-triazolo(4,3-a)(1,4)benzodiazepine
  • BRN 1226643
  • CCRIS 1932
  • Clorazolam
  • EINECS 249-307-3
  • Halcion
  • HSDB 6759
  • Novidorm
  • Songar
  • Triazolam
  • Triazolamum
  • Triazolamum [INN-Latin]
  • U 33030
  • U-33,030
  • UNII-1HM943223R

Systematic Names

  • 4H-(1,2,4)Triazolo(4,3-a)(1,4)benzodiazepine, 8-chloro-6-(2-chlorophenyl)-1-methyl-
  • 4H-s-Triazolo(4,3-a)(1,4)benzodiazepine, 8-chloro-6-(o-chlorophenyl)-1-methyl-
  • Triazolam

Superlist Names

  • DEA No. 2887
  • Triazolam

Registry Numbers

CAS Registry Number

  • 28911-01-5

FDA UNII

  • 1HM943223R

System Generated Number

  • 0028911015

Structure Descriptors

InChI

1S/C17H12Cl2N4/c1-10-21-22-16-9-20-17(12-4-2-3-5-14(12)19)13-8-11(18)6-7-15(13)23(10)16/h2-8H,9H2,1H3

InChIKey

JOFWLTCLBGQGBO-UHFFFAOYSA-N

Smiles

c12c(C(c3c(cccc3)Cl)=NCc3n1c(nn3)C)cc(Cl)cc2

Toxicity

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
human TDLo oral 7ug/kg (0.007mg/kg) BEHAVIORAL: SLEEP

BEHAVIORAL: "HALLUCINATIONS, DISTORTED PERCEPTIONS"

BRAIN AND COVERINGS: CHANGES IN SURFACE EEG
Journal of Clinical Pharmacology. Vol. 14, Pg. 102, 1974.
human TDLo oral 29ug/kg (0.029mg/kg) LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES

BEHAVIORAL: SLEEP

BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)
Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 38, Pg. 2597, 1996.
human TDLo oral 114ug/kg/4D-I (0.114mg/kg) BEHAVIORAL: TOXIC PSYCHOSIS British Medical Journal. Vol. 304, Pg. 1178, 1992.
man TDLo oral 1786ng/kg (0.001786mg/kg) BEHAVIORAL: "HALLUCINATIONS, DISTORTED PERCEPTIONS" Southern Medical Journal. Vol. 80, Pg. 1425, 1987.
man TDLo oral 3289ng/kg (0.003289mg/kg) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)

BEHAVIORAL: ALTERATION OF OPERANT CONDITIONING
Clinical Pharmacology and Therapeutics Vol. 49, Pg. 581, 1991.
man TDLo oral 7ug/kg (0.007mg/kg) LUNGS, THORAX, OR RESPIRATION: ACUTE PULMONARY EDEMA

BEHAVIORAL: COMA

LUNGS, THORAX, OR RESPIRATION: RESPIRATORY OBSTRUCTION
Journal of Toxicology, Clinical Toxicology. Vol. 33, Pg. 185, 1995.
man TDLo oral 100ug/kg (0.1mg/kg) CARDIAC: PULSE RATE

BEHAVIORAL: ATAXIA

BEHAVIORAL: SLEEP
Journal of Clinical Psychiatry. Vol. 47, Pg. 50, 1986.
man TDLo oral 107ug/kg (0.107mg/kg) BEHAVIORAL: COMA Archives of Internal Medicine. Vol. 145, Pg. 663, 1985.
man TDLo oral 357ug/kg (0.357mg/kg) BEHAVIORAL: COMA

BEHAVIORAL: "HALLUCINATIONS, DISTORTED PERCEPTIONS"

BEHAVIORAL: IRRITABILITY
Human & Experimental Toxicology. Vol. 11, Pg. 289, 1992.
mouse LD50 intraperitoneal 1625mg/kg (1625mg/kg)   Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 14, Pg. 484, 1983.
mouse LD50 oral 1080mg/kg (1080mg/kg) AUTONOMIC NERVOUS SYSTEM: "SMOOTH MUSCLE RELAXANT (MECHANISM UNDEFINED, SPASMOLYTIC)"

BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)
Cesko-Slovenska Farmacie. Vol. 37, Pg. 443, 1988.
mouse LD50 subcutaneous > 5gm/kg (5000mg/kg)   Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 25, Pg. 499, 1983.
rat LD50 intraperitoneal > 3300mg/kg (3300mg/kg)   Drugs in Japan Vol. -, Pg. 860, 1995.
rat LD50 oral > 7500mg/kg (7500mg/kg)   Yakkyoku. Pharmacy. Vol. 35, Pg. 1074, 1984.
rat LD50 subcutaneous > 5gm/kg (5000mg/kg)   Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 25, Pg. 499, 1983.
women TDLo oral 100ug/kg (0.1mg/kg) LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES

BEHAVIORAL: COMA

LUNGS, THORAX, OR RESPIRATION: CYANOSIS
American Journal of Emergency Medicine. Vol. 3, Pg. 210, 1985.

Physical Properties

Physical Property Value Units Temp (deg C) Source
log P (octanol-water) 2.42 (none)   EXP
Water Solubility 4.530 mg/L 25 EST
Vapor Pressure 4.50E-09 mm Hg 25 EST
Henry's Law Constant 7.24E-12 atm-m3/mole 25 EST
Atmospheric OH Rate Constant 4.97E-12 cm3/molecule-sec 25 EST

Physical property data is provided to ChemIDplus by SRC, Inc.